Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | CA7 | P43166 | 3/20 | 0.73 |
| ▸ | CA9 | Q16790 | 3/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA6 | P23280 | 2/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | FDPS | P14324 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959584 | 1.00 | CA12 (0.73) | CA12CA7CA9CA14CA1 | |
| SCHEMBL13957401 | 0.91 | CA12 (0.86) | CA12CA7CA9CA14CA1 | |
| SCHEMBL5059085 | 0.91 | CA12 (0.86) | CA12CA7CA9CA14CA1 | |
| SCHEMBL10939791 | 0.91 | CA12 (0.86) | CA12CA7CA9CA14CA1 | |
| SCHEMBL7842013 | 0.90 | CA12 (0.73) | CA12CA7CA9CA14CA1 | |
| SCHEMBL4613510 | 0.90 | CA12 (0.73) | CA12CA7CA9CA14CA1 | |
| SCHEMBL3143890 | 0.89 | CA12 (0.83) | CA12CA7CA9CA14CA1 | |
| SCHEMBL1260527 | 0.89 | CA12 (0.83) | CA12CA7CA9CA14CA1 | |
| SCHEMBL20358018 | 0.89 | CA12 (0.67) | CA12CA7CA9CA14CA1 | |
| SCHEMBL12521956 | 0.89 | CA12 (0.67) | CA12CA7CA9CA14CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7410984-B2 | Compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-08-12 | — | — | US | disclosed |
| EP-1737826-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20050288337-A1 | Novel compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005075438-A1 | ALPHA-4 INTEGRIN MEDIATED CELL ADHESION INHIBITORS FOR THE TREATMENT OR PREVENTION OF INFLAMMATORY DISEASES | TANABE SEIYAKU CO., LTD. (JP) | 2005-08-18 | — | — | WO | disclosed |
| EP-1539696-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
| WO-2004014859-A2 | PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288337-A1 | Novel compounds | ITGB4, ITGA4, ITGB5 | CA12 4852/4885CA7 4862/4885CA9 4816/4885 |
| US-20080234301-A1 | Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases | ITGB4, ITGA4, ICAM1 | CA12 3567/4885CA7 4428/4885CA9 3974/4885 |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | CA12 4777/4885CA7 3128/4885CA9 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.